<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04535947</url>
  </required_header>
  <id_info>
    <org_study_id>SDP-4-CS202</org_study_id>
    <nct_id>NCT04535947</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Efficacy of SDP-4 in Subjects With Dry Eye Disease (DED) (SDP-4-CS202)</brief_title>
  <official_title>A Phase 2, Multicenter, Double-Masked, Randomized, Vehicle-Controlled, Parallel Group, Study of SDP-4 Ophthalmic Solution in Subjects With Dry Eye Disease (DED)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Silk Technologies, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Silk Technologies, Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      SDP-4-CS202 is a Phase 2, multicenter, double-masked, randomized, vehicle-controlled,&#xD;
      parallel group study designed to evaluate the ocular efficacy of SDP-4 ophthalmic solution in&#xD;
      subjects with moderate to severe dry eye disease over an 8-week treatment period. Once&#xD;
      concentration (1%) of SDP-4 ophthalmic solution will be given in a parallel group to vehicle&#xD;
      via topical ocular instillation BID.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 14, 2020</start_date>
  <completion_date type="Actual">February 10, 2021</completion_date>
  <primary_completion_date type="Actual">February 10, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Subjects will be randomized to either 1% SDP-4 ophthalmic solution or vehicle in 1:1 ratio in parallel groups.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>All investigation product (1% SDP-4 ophthalmic solution and vehicle) will be provided in single-use doses (SUDs) contained in foil pouches.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Symptom Assessment in Dry Eye (SANDE) Questionnaire</measure>
    <time_frame>56 days</time_frame>
    <description>Mean change from baseline in total SANDE at Visit 5/Day 56</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Corneal fluorescein staining</measure>
    <time_frame>56 days</time_frame>
    <description>Mean and mean change from baseline at each visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tear Breakup Time</measure>
    <time_frame>56 days</time_frame>
    <description>Mean and mean change from baseline at each visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conjunctival hyperemia</measure>
    <time_frame>56 days</time_frame>
    <description>Mean and mean change from baseline at each visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Individual symptom Visual Analog Scale (VAS) scores, separately for each symptom</measure>
    <time_frame>56 days</time_frame>
    <description>Mean and mean change from baseline at each visit as measured on a scale from 0 to 100, where higher scores indicate a worse outcome</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">153</enrollment>
  <condition>Dry Eye</condition>
  <arm_group>
    <arm_group_label>Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SDP-4 Ophthalmic Solution (1.0%)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle</intervention_name>
    <description>Investigational product (IP) will be administered via topical ocular instillation, one drop per eye, twice daily (BID) for 8 weeks (56 days). Both eyes will be treated.</description>
    <arm_group_label>Vehicle</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SDP-4 Ophthalmic Solution (1.0%)</intervention_name>
    <description>Investigational product (IP) will be administered via topical ocular instillation, one drop per eye, twice daily (BID) for 8 weeks (56 days). Both eyes will be treated.</description>
    <arm_group_label>SDP-4 Ophthalmic Solution (1.0%)</arm_group_label>
    <other_name>SDP-4 (1.0%)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have DED in both eyes, as supported by a subject-reported history of daily symptoms of&#xD;
             dryeye for ≥ 6 months prior to Visit 1/Screening requiring the use of artificial&#xD;
             tears.&#xD;
&#xD;
          -  Total score ≥ 40 and ≤ 70 on the SANDE questionnaire at Visits 1 and 2.&#xD;
&#xD;
          -  Tear break-up time (TBUT) of ≤ 6 seconds in both eyes at Visits 1 and 2.&#xD;
&#xD;
          -  Anesthetized Schirmer's test tear volume ≥ 3 mm and &lt;10 mm in both eyes (only at Visit&#xD;
             1).&#xD;
&#xD;
          -  Best-corrected visual acuity (BCVA) of +0.7 logMAR or better in each eye as assessed&#xD;
             by logMAR chart at Visits 1 and 2.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Ocular surface corneal disease other than DED.&#xD;
&#xD;
          -  Diagnosis of Sjögren's disease.&#xD;
&#xD;
          -  Lid margin disorder other than meibomian gland dysfunction (MGD)&#xD;
&#xD;
          -  Presence of any ocular condition (e.g., pterygium) that in the Investigator's opinion&#xD;
             could affect study parameters.&#xD;
&#xD;
          -  Any previous reconstructive or cosmetic eyelid surgery&#xD;
&#xD;
          -  Any previous invasive glaucoma and/or corneal surgery&#xD;
&#xD;
          -  Corneal refractive surgery in the 12 months prior to Visit 1/Screening.&#xD;
&#xD;
          -  Cataract extraction within 90 days prior to Visit 1/Screening.&#xD;
&#xD;
          -  Cauterization of the punctum or punctal plug (silicone or collagen) insertion or&#xD;
             removal within 30 days prior to Visit 1/Screening or planned during the study.&#xD;
&#xD;
          -  Contact lens wear.&#xD;
&#xD;
          -  Use of ophthlamic corticosteroids, NSAIDs, antibiotics, antihistamines, IOP lowering&#xD;
             medication, in the 30 days prior to Visit 1/Screening&#xD;
&#xD;
          -  Serious systemic disease or uncontrolled medical condition that in the judgment of the&#xD;
             Investigator could confound study assessments&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Orange County Ophthalmology Medical Group</name>
      <address>
        <city>Garden Grove</city>
        <state>California</state>
        <zip>92843</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LoBue Laser and Eye Medical Center</name>
      <address>
        <city>Murrieta</city>
        <state>California</state>
        <zip>92562</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eye Research Foundation</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ophthalmology Associates</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Total Eye Care</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>August 27, 2020</study_first_submitted>
  <study_first_submitted_qc>August 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 2, 2020</study_first_posted>
  <last_update_submitted>May 13, 2021</last_update_submitted>
  <last_update_submitted_qc>May 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Eye Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

